Alnylam Pharmaceuticals
ALNY
#814
Rank
NZ$53.62 B
Marketcap
NZ$400.77
Share price
0.23%
Change (1 day)
-47.13%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$6.60

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$6.41. In 2025 the company made an earnings per share (EPS) of NZ$3.04.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.60116.97%
2025NZ$3.04
2023NZ-$5.97-62%
2022NZ-$15.7029.03%
2021NZ-$12.17-3.36%
2020NZ-$12.59-8.48%
2019NZ-$13.767.67%
2018NZ-$12.7839.74%
2017NZ-$9.1412.94%
2016NZ-$8.1038.84%
2015NZ-$5.83-32.88%
2014NZ-$8.69259.44%
2013NZ-$2.42-31.25%
2012NZ-$3.52

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$11.87 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$4.33-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$71.89 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$0.96-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.23-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.46-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.32-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$1.37-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA